Provided are antibodies that specifically bind to Programmed Death 1 (PD1 Pdcd-1, or CD279) and inhibit PD1 mediated cellular signaling and activities in immune cells antibodies binding to a set of amino acid residues required for its ligand binding and uses of these antibodies to treat or diagnose cancer infectious diseases or other pathological disorders modulated by PD1 mediated functions.